M&A Deal Summary |
|
---|---|
Date | 2019-07-29 |
Target | Genomic Health |
Sector | Life Science |
Buyer(s) | Exact Sciences |
Deal Type | Add-on Acquisition |
Deal Value | 2.8B USD |
Advisor(s) | Goldman Sachs (Financial) Sullivan & Cromwell Pillsbury Winthrop Shaw Pittman (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1995 |
Sector | Life Science |
Employees | 6,500 |
Revenue | 2.5B USD (2023) |
Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Exact Sciences was founded in 1995 and is based in Madison, Wisconsin.
DEAL STATS | # |
---|---|
Overall | 2 of 8 |
Sector (Life Science) | 2 of 6 |
Type (Add-on Acquisition) | 2 of 7 |
State (California) | 2 of 2 |
Country (United States) | 2 of 7 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2018-10-18 |
Biomatrica
San Diego, California, United States Biomatrica, Inc. is a provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-03-03 |
Paradigm Diagnostics
Phoenix, Arizona, United States Paradigm Diagnostics, Inc. is a medical diagnostics company serving physicians and patients worldwide. The company provides the Paradigm Cancer Diagnostic (PCDx) next-generation sequencing assay to assist physicians and cancer patients to target each patient's specific tumor pathways and genomic changes in their cancer. Through PCDx we assist physicians, patients, and organizations to better understand those fundamental pathways that drive a patient's specific cancer and allow for more effective clinical decision making. |
Buy | - |